IM Cannabis Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

IM Cannabis heeft een totaal eigen vermogen van CA$4.2M en een totale schuld van CA$15.2M, wat de schuld-eigenvermogensverhouding op 360.3% brengt. De totale activa en totale passiva bedragen respectievelijk CA$44.6M en CA$40.4M.

Belangrijke informatie

360.3%

Verhouding schuld/eigen vermogen

CA$15.17m

Schuld

Rente dekkingsratio	n/a
Contant	CA$1.96m
Aandelen	CA$4.21m
Totaal verplichtingen	CA$40.43m
Totaal activa	CA$44.64m

Recente financiële gezondheidsupdates

Recent updates

IM Cannabis Shareholder Rafael Gabay raises stake

Sep 08

IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M

Aug 15

IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement

Jul 19

cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets

Aug 14

IM Cannabis proposes public offering of securities

May 05

IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia

Apr 30

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$27.6M ) van IMCC } dekken niet de korte termijn passiva ( CA$39.2M ).

Langlopende schulden: De kortetermijnactiva IMCC ( CA$27.6M ) overtreffen de langetermijnschulden ( CA$1.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 313.8% ) IMCC wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van IMCC is de afgelopen 5 jaar gestegen van 0% naar 360.3%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende IMCC voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: IMCC is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 0.1 % per jaar groeit.

IM Cannabis Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2024 Results on Nov 14, 2024

IM Cannabis Corp. announced that it expects to receive $1.613 million in funding

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

IM Cannabis Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction.

New major risk - Share price stability

IM Cannabis Announces Receipt of Court Action

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2023 Results on Nov 13, 2023

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

New major risk - Market cap size

IM Cannabis Corp. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Financial position

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Corp. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Commences Exit of Canadian Cannabis Market to Focus its Resources on Pursuing Growth Opportunities in Israel, Germany and Europe

IM Cannabis Corp. to Report Q3, 2022 Results on Nov 14, 2022

High number of new directors

High number of new directors

CEO & Director recently bought US$118k worth of stock

Executive Chairman recently bought US$80k worth of stock

IM Cannabis Corp. Announces Board Changes

IM Cannabis Shareholder Rafael Gabay raises stake

IM Cannabis Corp. announced that it expects to receive $5 million in funding

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M

IM Cannabis Corp., Annual General Meeting, Oct 20, 2022

IM Cannabis Corp. to Report Q2, 2022 Results on Aug 15, 2022

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement

First quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

IM Cannabis Corp. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO & Director recently bought US$336k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IM Cannabis Corp. Provides Earnings Guidance for Fourth Quarter of 2021 and Full Year 2022

Third quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.017 profit in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Insider recently sold US$60k worth of stock

Second quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in 2Q 2020)

cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets

IM Cannabis Corp. Unveils Proprietary Data from A Clinical Survey Evaluating Medicinal Cannabis Therapy

First quarter 2021 earnings released: EPS CA$0.11 (vs CA$0.011 loss in 1Q 2020)

IM Cannabis Corp. Provides Earnings Guidance for the Second Quarter of 2021

IM Cannabis proposes public offering of securities

IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia

Full year 2020 earnings released: CA$0.74 loss per share (vs CA$0.23 loss in FY 2019)

IM Cannabis Corp. Provides Preliminary Earnings Guidance for the First Quarter and Second Quarter of 2021

IM Cannabis Corp. (CNSX:IMCC) completed the acquisition of Trichome Financial Corp. (CNSX:TFC) from Cresco Labs Inc., Opaskawayak Cree Nation and others.

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. to Bring Canadian Premium Indoor High-THC Medical Cannabis to Israel with Imports from GTEC Holdings Ltd

New 90-day high: US$10.26

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp Announce That the Israeli Ministry of Health Has Launched A New Pilot Program

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven